- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05028972
Compromissione dell'udito, strategie e risultati nei dipartimenti di emergenza VA (HearVA-ED)
Implementazione di HearVA (I-HearVA)
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
HearVA is a randomized controlled trial to explore the utility and outcomes of providing point-of-care access to hearing-impaired Veterans, comparing an offer of personal amplifiers versus control in an environment where the clinical stakes are high. It addresses a knowledge gap about the utility of providing such hearing assistance during clinical encounters. The study measures whether providing personal amplifiers is acceptable to older patients, can improve hearing, enhance understanding of discharge instructions, and improve care transitions at discharge. If such a strategy is beneficial, this simple low-tech approach has great potential for implementation and wide dissemination. HearVA-ED has two phases - the first, which has been completed, established the feasibility and acceptability of research and procedures in the ED environment through a pilot efficacy study and the second phase will be to complete a larger more definitive efficacy study and a detailed implementation study resulting in a strategic approach that can be widely disseminated across all VA emergency departments throughout the United States. This second phase will use a mixed-methods, hybrid effectiveness-implementation design to implement and evaluate the hearing assistance intervention in six VA Emergency Department Sites (in different facilities across the country). Implementation will occur in four stages with variation in the starting sequence at each site: The first group of two VA emergency departments will initiate implementation with an efficacy trial; second group of two sites will initiate implementation with delivery and support of personal amplifiers after screening and randomization by a research assistant (Stage 1); the third group of two sites will initiate implementation with the entire implementation (Stage 2) and the presence of a research assistant to conduct discharge interviews; and all sites will progress from this sequence to Stage 3 - Sustainability - which is the full implementation without research assistant presence.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Joshua Chodosh, MD MSHS
- Numero di telefono: 48491 (310) 478-3711
- Email: Joshua.Chodosh@va.gov
Backup dei contatti dello studio
- Nome: Lin T Tun
- Numero di telefono: (646) 501-4132
- Email: lin.tun@va.gov
Luoghi di studio
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045-7211
- Reclutamento
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contatto:
- Lauren Abbate, MD
- Numero di telefono: 3177 303-399-8020
- Email: lauren.abbate@va.gov
-
-
New York
-
New York, New York, Stati Uniti, 10010-5011
- Reclutamento
- VA NY Harbor Healthcare System, New York, NY
-
Investigatore principale:
- Joshua Chodosh, MD MSHS
-
Contatto:
- Olga Dotsenko
- Numero di telefono: 3323 (212) 686-7500
- Email: olga.dotsenko@va.gov
-
Contatto:
- Andrea M Aquines
- Numero di telefono: (212) 686-7500
- Email: andrea.aquines@va.gov
-
Syracuse, New York, Stati Uniti, 13210-2716
- Attivo, non reclutante
- Syracuse VA Medical Center, Syracuse, NY
-
The Bronx, New York, Stati Uniti, 10468
- Reclutamento
- James J. Peters VA Medical Center, Bronx, NY
-
Contatto:
- Ula Hwang, MD
- Numero di telefono: 3816 718-584-9000
- Email: ula.hwang@va.gov
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705-3875
- Reclutamento
- Durham VA Medical Center, Durham, NC
-
Contatto:
- Luna Ragsdale, MD
- Email: luna.ragsdale@va.gov
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75216-7167
- Reclutamento
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Contatto:
- Rohit Manaktala, MD
- Email: Rohit.Manaktala@va.gov
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- English speaking
- Emergency severity index criterion of 3 (medium), 4, or 5 (low acuity)
- Hearing Handicap Inventory-Screen greater than or equal to 10 or positive answer to a single-item screening question
- Capacity to consent to participate in research
Exclusion Criteria:
- Inability to consent to participate in research
- Emergency severity index criterion of 1-2 (high acuity)
- Hearing Handicap Inventory-Screen less than 10 and negative answer to single item screening question
- Inability to speak English
- Using cochlear implants
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervention: Personal Amplifier
Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department |
The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
Altri nomi:
|
|
Altro: Control: No Personal Amplifier
Consenting participants will be randomly assigned to the control group while receiving care in the emergency department |
The control group will not receive personal amplifiers while they receive care in the ED |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Emergency department (ED) 3-day Readmissions
Lasso di tempo: 3-5 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within three days through CPRS review as well as a brief follow-up phone call 3-5 days after ED discharge |
3-5 days after initial ED stay
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Emergency department (ED) 30-day Readmissions
Lasso di tempo: 30-35 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within 30 days through CPRS review as well as a brief follow-up phone call 30-35 days after ED discharge |
30-35 days after initial ED stay
|
|
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During Emergency department (ED) Stay
Lasso di tempo: Duration of ED stay, average of 1 day
|
Participants will self-rate their quality of hearing, understanding, and communication using a six item questionnaire. Scored on a 10-point Likert scale (1 = do not agree at all; 10 = completely agree) the questions will be: When I talked to the doctors and nurses today ... (1) their voices were very clear; (2) I was able to hear the sounds that I wanted to hear; (3) noises did not cause a problem for my hearing; and (4) listening did not make me tired. Two additional statements will explicitly capture understanding: (5) I was able to understand what they said; and (6) I was able to understand without making an effort. Higher scores will indicate better communication and understanding with providers. |
Duration of ED stay, average of 1 day
|
|
Patient-Rated Quality of Post-Discharge Care
Lasso di tempo: At time of discharge from ED, average 1 day
|
Patient-rated quality of post-discharge care using a three-item subset of the Care Transition Measure (CTM). The questions are scored on a 1-4 scale (1= strongly disagree; 4 = strongly agree): (1) The ED staff considered my preferences and those of my family or caregiver in deciding what my healthcare needs were for discharge; (2) Leaving the ED, I have a good understanding of the things I am responsible for in managing my health; (3) Leaving the ED, I clearly understand the purpose for each of my medications. Higher scores will indicate better discharge preparation. |
At time of discharge from ED, average 1 day
|
|
Self-Reported Understanding of Discharge Instructions
Lasso di tempo: 3-5 days after initial ED stay
|
Investigators will gauge self-reported understanding of discharge instructions using semi-structured interview data compared to documented discharge data. |
3-5 days after initial ED stay
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Joshua Chodosh, MD MSHS, VA NY Harbor Healthcare System, New York, NY
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IIR 17-068-1
- HX002421 (Altro numero di sovvenzione/finanziamento: VA HSR&D)
- 5I01HX002421-08 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .